Besides their role in the pathogenesis of AML karyotype aberrations are the most important independent factors determining the prognosis of patients receiving chemotherapy or stem cell transplantation ...
Event-free survival (EFS) events included molecular or hematological relapse or death. Cumulative incidence of hematological relapse (CIHR) was calculated using the gray test, with death in remission ...
– Clinical observations from preliminary data at the lowest dose of MGTA-117 in a Phase 1/2 clinical trial indicate target binding, reduction of target cells in bone marrow, rapid drug clearance and a ...
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem ...
Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...
Utrecht, The Netherlands, January 7, 2013 – Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that it has selected MCLA-117 as lead candidate ...
A chromosome is a package of DNA that exists inside the nucleus of a cell. A karyotype refers to the unique collection of chromosomes present in a person’s cells. Acute myeloid leukemia (AML) is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results